TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03613883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular management
Description: Embolic materials (coils / glue): the glue will be routinely used when access into the aneurysm's outflow vessel will be unattainable.~Endovascular stent to slow the flow inducing thrombosis of the sac of aneurysm. CT angiography will be performed later to evaluate and confirm the diagnosis and viability of the endovascular procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular management
Description: Embolic materials (coils / glue): the glue will be routinely used when access into the aneurysm's outflow vessel will be unattainable.~Endovascular stent to slow the flow inducing thrombosis of the sac of aneurysm. CT angiography will be performed later to evaluate and confirm the diagnosis and viability of the endovascular procedure
Study: NCT00819780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab is a fully human immunoglobulin G (IgG)2 monoclonal antibody antagonist directed against human Epidermal Growth Factor receptor (EGFr).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is a humanized monoclonal IgG1 antibody that is directed against Vascular Endothelial Growth Factor (VEGF).
Study: NCT03178084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD
Description: maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
Study: NCT01770990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tel-PT including mail
Description: Patients receive telephone-based psychotherapy and one letter after each telephone session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tel-PT without mail
Description: Patients receive telephone-based psychotherapy without additional letters.
Study: NCT02349724

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Anti-CEA-CAR T
Description: T cells modified with CEA targeted chimeric antigen receptor.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Anti-CEA-CAR T
Description: T cells modified with CEA targeted chimeric antigen receptor.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Anti-CEA-CAR T
Description: T cells modified with CEA targeted chimeric antigen receptor.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Anti-CEA-CAR T
Description: T cells modified with CEA targeted chimeric antigen receptor.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Anti-CEA-CAR T
Description: T cells modified with CEA targeted chimeric antigen receptor.
Study: NCT02191384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orcinoside
Description: oral, twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orcinoside
Description: oral, twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orcinoside
Description: oral, twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orcinoside
Description: oral, twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orcinoside
Description: oral, twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orcinoside
Description: oral, twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Orcinoside
Description: oral, twice per day
Study: NCT01494714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 10229570-AAA 1.2% cream
Description: A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 10229570-AAA 2.4% cream
Description: A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 10229570-AAA 3.6% cream
Description: A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Color-matched vehicle in a cream formulation containing 0 mg of JNJ 10229570-AAA
Description: A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petroleum jelly
Description: A patch containing the petroleum jelly will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
Study: NCT03230422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: normal airway
Description: The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: normal airway
Description: The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: difficult airway
Description: The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: difficult airway
Description: The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
Study: NCT02550873

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRM-151
Description: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks
Study: NCT00798486

Intervention type: DEVICE
Group type: OTHER
Intervention: A1C Test Kit
Description: Subjects tested 3 times with A1C test kits. Two tests were performed by the subject and the third test was performed by a healthcare professional (HCP). All results were compared to results from a laboratory glucose analyzer (TOSOH).
Study: NCT04545216

Intervention type: OTHER
Intervention: Long-distance mountain running
Description: Impact of a mountain race on the knee cartilage

Intervention type: OTHER
Intervention: Long-distance mountain running
Description: Impact of a mountain race on the knee cartilage

Intervention type: OTHER
Intervention: Long-distance mountain running
Description: Impact of a mountain race on the knee cartilage
Study: NCT04657523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Liver Fat Quantification Software
Description: All subjects enrolled in this study will undergo two abdominal ultrasound examinations using the investigational Liver Fat Quantification feature on the Philips EPIQ Ultrasound System. In addition, all subjects will also undergo one MRI-PDFF examination according to the clinical standard of care.
Study: NCT04320615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Description: Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.
Study: NCT00819780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.
Study: NCT04320615

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
Study: NCT02699541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Education
Description: This study will implement an individualized DSME program based on Information-Motivation-Behavioral (IMB) skills theory. IMB behavioral change theory assumption proposes that health-related behavior information, motivation and behavioural skills are primary determinants of promoting health behavior.~Researcher will use a previously validated educational toolkit (PRIDE) and will be delivered using motivational interviewing techniques through several sessions for each participant. Two face-to-face sessions (one at the beginning and one at the end of the 3 month period) and one phone call per week or per fortnight.
Study: NCT00895843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brufen retard
Description: Single dose 2 x 800mg tablets 2 hours prior to surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen
Description: Single dose ibuprofen 2 x 200mg tablets 2 hours prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Up to 10ml of Bupivacaine 0.5% with 1:200,000 Adrenaline given prior to surgical incision as inferior alveolar nerve block and long buccal nerve infiltration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Up to 10ml of Bupivacaine 0.5% with 1:200,000 Adrenaline given prior to surgical incision as inferior alveolar nerve block and long buccal nerve infiltration.
Study: NCT01537627

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: Aerobic exercises (treadmill and cycloergometer): Initially, the intensity is targeted at 60% of maximal capacity and it increases weekly until 110% of maximal capacity. Exercises duration: at least, 20 minutes.~Resistive exercises (multi gym station; muscle groups: biceps, triceps and quadriceps): Initially, the intensity is targeted at 70% of one maximum repetition (1RM) and it increases weekly until 121% of 1RM. Exercises duration: 3 sets of 8 repetitions. Both exercise training are performed 3 times per week during 6 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: Callisthenic and breathing exercises are performed during 1 hour, 3 times per week during 6 months. The exercises are divided in 7 different sets and the degree of difficulty of the exercises progresses according to the set.
Study: NCT00264160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMN107
Study: NCT03808350

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Families Invited to Be Present at Procedures
Description: Family members will be invited (but not required) to remain in the ICU room during procedures, if patients agree

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Control
Description: Family members will not be invited to remain in the ICU room
Study: NCT01633008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Workshop
Description: The ACT workshops will consist of a patient program and a corresponding parent program, each focusing on helping participants cope with the patient s pain more effectively using ACT techniques
Study: NCT05073029

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition program and modification of physical activity
Description: nutrition program developed by a gastroenterologist-nutritionist and modification of physical activity (8000-10000 steps daily)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: synbiotic (Fructooligosaccharides+Lactobacillus rhamnosus GG ATCC 53103, 4.0х109 colony forming units - CFU)
Description: one synbiotic sachet (3g), BID, for 3 month traetment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: vitamin D3, oral, 2000IU BID, for 3 month treatment
Study: NCT01007136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
Study: NCT04298450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active SMS Intervention
Description: Welcome message letting participant know they will be contacted to book an appointment, followed by appointment reminders and other clinic information, psychoeducational materials, and a distress check-in with two-way feedback to their care team, all sent by SMS/text message at the participant's preferred time of day. If they indicate that they are in high distress, or they request, their care provider will be notified and asked to reach out to them. They will also receive crisis resources.The intervention will continue until the patient attends the first consultation appointment, or for up to 30 days if the patient does not attend, which reflects the program's practice of closing referrals for non-attending patients.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham SMS
Description: Single welcome message letting participant know they will be contacted to book an appointment.
Study: NCT02870816

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Engineered Skin Substitute
Description: Application of skin substitute and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Offloading
Description: Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Offloading
Description: Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amnionic Membrane Graft
Description: Application of amnion membrane graft and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
Study: NCT00932698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules
Study: NCT04080674

Intervention type: OTHER
Intervention: Feed-back controlled deep brain stimulation
Description: Feed-back controlled deep brain stimulation

Intervention type: OTHER
Intervention: Feed-back controlled deep brain stimulation
Description: Feed-back controlled deep brain stimulation

Intervention type: OTHER
Intervention: Feed-back controlled deep brain stimulation
Description: Feed-back controlled deep brain stimulation
Study: NCT03873415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Oral administration
Study: NCT01577615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patterned Experience
Description: * The caregiver's hand over the shoulder area and the other hand over the lower extremities during feeding in the incubator, swaddling or holding outside the incubator.~* Nonnutritive sucking will be offered to infants.~* Blood work will be collected for inflammatory cytokines.~* Saliva will be collected for genetic analysis~* Saliva will be collected in 10 infant sub study for cortisol pre and post feedings~* All scheduled feedings will include an opportunity for the infant to try feeding orally by bottle or breast while being held in a swaddled flexed position.~* Once bottle feedings are initiated, infants will be observed twice a week utilizing the computer data acquisition system.~* Follow up visits will occur at 2,6and 24 months corrected age.
Study: NCT03573219

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-wave diathermy
Description: The application of SWD will be carried out by a CEC M-8 short-wave thermotherapy unit. The device has capacitive applicators, that will be situated around the muscle to be irradiated on top of a cotton towel, in order to absorb perspiration and avoid undesired heating effects. Afterwards the emission mode (continuous or pulsed) will be selected, and application of SWD will start. The intensity of SWD will be gradually increased until the volunteer perceives a warm sensation, and once familiarized with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the duration of the SWD application, estimated in approximately 10 minutes.
Study: NCT05392439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: transcutaneous auricular vagal nerve stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-taVNS
Description: transcutaneous stimulation at the elbow area
Study: NCT03161002

Intervention type: GENETIC
Intervention: detection of genotype
Description: detection of genotype by next generation sequencing

Intervention type: GENETIC
Intervention: detection of genotype
Description: detection of genotype by next generation sequencing
Study: NCT01609309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Description: * After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open gastrectomy
Description: * After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience.
Study: NCT01306045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD6244
Description: Cycle = 21 days AZD6244 Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-2206
Description: Cycle = 28 days MK-2206 200 mg by mouth (PO) every (Q) Week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Cycle = 21 days Lapatinib 1500 mg by mouth (PO) every day (QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Cycle = 21 days Erlotinib 150 mg by mouth (PO) every morning (QAM)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Cycle = 42 days Sunitinib 50 mg by mouth (PO) on days 1-28

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Molecular Profiling
Description: Molecular profiling of tumor tissue. Not Otherwise Specified (NOS) arm. Participants who do not meet the eligibility criteria for enrollment or who meet eligibility criteria for a particular arm but can't be enrolled

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Molecular Profiling
Description: Molecular profiling of tumor tissue. Not Otherwise Specified (NOS) arm. Participants who do not meet the eligibility criteria for enrollment or who meet eligibility criteria for a particular arm but can't be enrolled

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Molecular Profiling
Description: Molecular profiling of tumor tissue. Not Otherwise Specified (NOS) arm. Participants who do not meet the eligibility criteria for enrollment or who meet eligibility criteria for a particular arm but can't be enrolled

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Molecular Profiling
Description: Molecular profiling of tumor tissue. Not Otherwise Specified (NOS) arm. Participants who do not meet the eligibility criteria for enrollment or who meet eligibility criteria for a particular arm but can't be enrolled

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Molecular Profiling
Description: Molecular profiling of tumor tissue. Not Otherwise Specified (NOS) arm. Participants who do not meet the eligibility criteria for enrollment or who meet eligibility criteria for a particular arm but can't be enrolled

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Molecular Profiling
Description: Molecular profiling of tumor tissue. Not Otherwise Specified (NOS) arm. Participants who do not meet the eligibility criteria for enrollment or who meet eligibility criteria for a particular arm but can't be enrolled